Goodbye Gleevec? Sprycel, Tasigna Vie For Front-Line CML Leadership
This article was originally published in The Pink Sheet Daily
Executive Summary
BMS' Sprycel and Novartis' Tasigna perform better on key endpoints than standard of care, Gleevec, in first-line treatment of chronic myeloid leukemia.